evipedia.aidev
← Back

Young Plasma Transfusion for Health & Longevity

Evidence Review created on 08/15/2026 using AI4L / Grok 4

Also known as: Young Blood Transfusion, Young Donor Plasma Infusion, Young Plasma Infusion, Young Fresh Frozen Plasma, yFFP, Heterochronic Plasma Transfer

Motivation

Young plasma transfusion is the intravenous infusion of plasma — the cell-free liquid of blood — taken from a younger donor, usually someone in late adolescence or the twenties, into an older adult. Interest comes from mouse work in which a young circulation appeared to refresh muscle repair, heart structure, and learning. Longevity-minded adults have treated that animal signal as a possible systemic reset.

Clinics later sold the procedure for several thousand dollars per session, while academic groups ran small safety studies in people with memory and movement disorders. A separate line of experiments argues that washing out old plasma matters more than adding young plasma. The US Food and Drug Administration has twice said it has not approved young-donor plasma for aging or memory claims.

This review examines what young plasma transfusion is, how the two proposed biological explanations differ, what human and animal evidence exists for benefit and harm, and how the procedure compares with related blood-exchange methods.

Benefits - Risks - Protocol - Conclusion

High-level overviews that place young plasma transfusion in the parabiosis (surgical joining of two animals so they share blood), clinic, and competing-dilution landscape.

Chris Kresser discussed parabiosis only in passing as background for plasmapheresis, not young plasma transfusion.

Grokipedia

  • Young blood transfusion

    Grokipedia’s entry compiles the animal literature, commercial clinics, and the FDA unapproved-use warning in one place.

Examine

No dedicated Examine.com article on young plasma transfusion was found. Examine.com does not typically cover blood-bank biologics.

ConsumerLab

No dedicated ConsumerLab article on young plasma transfusion was found. ConsumerLab does not typically cover blood products or transfusion procedures.

Systematic Reviews

Systematic reviews of blood-derivative trials in Alzheimer disease and of transfusion-reaction rates for licensed plasma products.

Mechanism of Action

Young plasma transfusion delivers the acellular portion of blood from a younger donor into an older recipient, adding circulating proteins, metabolites, lipids, and extracellular vesicles (tiny cell-derived packets) without transferring red cells or platelets. Two mechanistic accounts compete.

The first holds that youth-associated proteins restore aged stem-cell niches. In mice, young plasma raises hippocampal CREB (a transcription factor that helps encode memories) signaling, synapse number, and learning. Candidate factors include TIMP2 (tissue inhibitor of metalloproteinase 2, a matrix-remodeling protein concentrated in cord plasma), platelet factor 4, and, controversially, GDF11 (growth differentiation factor 11, a member of the TGF-β (transforming growth factor beta) family). The second holds that old plasma is dominated by inhibitory cues such as CCL11 (eotaxin, a chemokine that rises with age), beta-2-microglobulin, and TGF-β, so dilution or exchange — not addition of young factors — explains most of the parabiosis effect. Isolated blood exchange and saline-albumin dilution can match or exceed young-plasma benefits in mice (Mehdipour et al.), and old blood rapidly induces senescence programs in young tissues (Jeon et al.).

A simple young-plasma infusion increases circulating volume and young-factor levels while leaving most of the recipient’s old plasma in place, so it tests the additive model more than the dilution model. Circulating protein half-lives range from minutes for many cytokines to about three weeks for albumin and immunoglobulin G; any pulse of young factors is therefore transient unless infusions are repeated.

Historical Context & Evolution

McCay’s mid-century rat parabiosis experiments first suggested that a shared circulation could alter aging. The modern field reopened in 2005, when heterochronic parabiosis (surgical joining of a young and an old mouse so they share blood) restored muscle and liver progenitor activity in the old partner. Subsequent Stanford and Harvard work showed that young blood improved hippocampal plasticity and, in one line of experiments, reversed age-related heart-muscle thickening, first attributed to GDF11. Those animal findings — not a prior medical use of young plasma for aging — are why longevity clinics later sold the procedure.

Commercial programs such as Ambrosia began offering young-donor plasma to paying adults around 2016, typically at several thousand dollars per infusion. In 2019 the US Food and Drug Administration warned that no well-controlled evidence supported claims for aging, memory loss, or neurodegenerative disease, and it restated that position in 2024. Parallel academic work split: Wyss-Coray and collaborators pursued young-plasma fractions through Alkahest, a company Wyss-Coray co-founded and that Grifols later acquired, while Conboy and colleagues argued that neutralizing old-plasma inhibitors, including by therapeutic plasma exchange with albumin, better explains the animal data. Human studies to date have been small safety and feasibility trials, not longevity outcomes. Neither camp has produced a decisive human comparison of adding young plasma versus removing old plasma.

Expected Benefits

Human benefit data are exploratory, small, and largely from groups tied to plasma-fraction companies. Animal signals are stronger but have not been reproduced as longevity outcomes in people.

Low 🟩

Daily-function scores in Alzheimer disease ⚠️ Conflicted

Young plasma was tested in a small Stanford Alzheimer series run with Alkahest. Youth-associated circulating proteins are the proposed driver. Two daily-living questionnaires improved within the treated group, but the study was not powered for efficacy, half of participants were unblinded, and saline contrasts were not shown. (Sha et al.)

Magnitude: Not quantified in available studies. The literature reports no between-group effect size versus saline; reported gains were uncorrected within-group changes.

Language fluency in Parkinson disease

Open-label Stanford series of 15 people with Parkinson disease received eight young-plasma units over four weeks, aiming to restore circulating youth-associated proteins. Phonemic fluency (naming words that start with a given letter) improved; motor scores and most cognitive tests did not. There was no control arm. (Parker et al.)

Magnitude: Direction holds after a short open-label course; the literature reports no controlled effect size.

Speculative 🟨

Hippocampal plasticity and learning

Repeated young-plasma injection improves learning and hippocampal synapses in aged mice. Human longevity trials have not tested these endpoints. Basis is animal work only. (Villeda et al.)

Muscle and liver progenitor activity

Heterochronic parabiosis restores Notch (a stem-cell activation pathway) signaling and muscle-satellite and liver-progenitor activity in old mice. Isolated young-plasma transfusion is less studied than shared circulation. Basis is animal work only. (Conboy et al.)

Cardiac hypertrophy reversal ⚠️ Conflicted

Young circulation reversed age-related heart-muscle thickening in mice, first attributed to GDF11. Later assays found GDF11 may rise with age and impair regeneration. Basis is conflicting animal work only. (Loffredo et al.; Egerman et al.)

Epigenetic or biological age

Commercial programs advertise a younger biological age. No completed, published, controlled human trial of young plasma has shown clock reversal. Basis is marketing and unpublished listings only.

Mean lifespan in old rodents

Old rats given young plasma lived longer on average and showed a younger blood DNA-methylation pattern. No controlled human survival study exists. Basis is one animal colony study. (Chiavellini et al.)

Benefit-Modifying Factors

  • APOE genotype: APOE4 (apolipoprotein E epsilon-4, a lipid-transport variant that raises Alzheimer risk) was an enrollment factor in a tiny Mayo infusion-versus-exchange pilot (NCT03887741); no large pharmacogenetic map exists.
  • Baseline inflammatory tone: People with higher TNF-α (tumor necrosis factor alpha, a circulating inflammatory cytokine) had room to fall in the open-label Parkinson series; quieter proteomes may show less change.
  • Sex: Licensed plasma is often restricted to male donors to cut lung-injury risk. Recipient-sex differences in longevity benefit have not been measured.
  • Pre-existing neurologic disease: Human series enrolled Alzheimer or Parkinson diagnoses. Effects in cognitively healthy older adults have not been measured.
  • Age: Animal gains are largest in frankly aged mice. Human participants were typically 50–90 years; volume-overload risk rises with age.

Potential Risks & Side Effects

Plasma is a licensed blood component with a well-mapped hospital safety record. Those harms apply to young-donor units as well.

High 🟥 🟥 🟥

Allergic and anaphylactic transfusion reactions

Plasma commonly triggers type I hypersensitivity (an immediate allergic reaction) to soluble proteins. In a meta-analysis of plasma products, allergic reactions occurred at about 92 per 100,000 units and anaphylaxis (a severe, whole-body allergic reaction) at about 0.8 per 100,000. In the Stanford Alzheimer trial, one of 18 participants stopped because of urticaria (hives). Reactions are usually mild and reverse when the infusion stops; IgA (immunoglobulin A) deficiency raises anaphylaxis risk. (Saadah et al.)

Magnitude: About 92 allergic reactions and 0.8 anaphylactic reactions per 100,000 plasma units.

Transfusion-associated circulatory overload

Volume expansion can flood the pulmonary circulation, especially in older adults with stiff ventricles or kidney disease. Active-surveillance meta-analysis estimates TACO (transfusion-associated circulatory overload, fluid backup into the lungs) at about 22 per 1,000 transfused patients and 2.2 per 1,000 units across components. TACO is a leading transfusion-related cause of death. (White et al.)

Magnitude: About 22 TACO events per 1,000 transfused patients under active surveillance (all components).

Medium 🟥 🟥

TRALI (transfusion-related acute lung injury) is sudden respiratory failure from donor leukocyte antibodies or bioactive lipids. Plasma from previously pregnant donors carries higher risk. Male-only plasma cuts TRALI substantially versus mixed-sex plasma. Modern active-surveillance estimates for plasma are about 3 per 10,000 units. (White et al.)

Magnitude: About 3.19 TRALI events per 10,000 plasma units under active surveillance; male-only plasma lowers risk.

Hemolytic reactions from blood-group–incompatible plasma

Donor anti-A or anti-B antibodies in plasma can destroy the recipient’s red cells when the unit is ABO-incompatible (mismatched to the A/B/O blood-group system). A scoping review of plasma-containing components documented hemolysis from as little as 100 mL of high-titer incompatible plasma in adults, with deaths in a minority of published cases. ABO-matched units, as used in academic young-plasma protocols, make this event rare. (McCullagh et al.)

Magnitude: Hemolysis has been reported after as little as 100 mL of high-titer ABO-incompatible plasma in adults; 24% of published cases were fatal.

Residual infectious transmission

Screened, licensed US plasma still carries residual risk of hepatitis, HIV, HEV (hepatitis E virus), bacteria, and theoretically prions. Pathogen-reduced plasma lowers but does not eliminate this. Private-clinic young-plasma programs outside licensed blood systems may skip standard infectious-disease testing. (Gallian et al.)

Magnitude: Residual viral risk after licensed screening is far below 1 per million units for HIV and hepatitis C; HEV and bacteria remain documented exceptions.

Low 🟥

Febrile nonhemolytic reactions

Fever without hemolysis is a recognized plasma reaction, driven by donor cytokines or recipient antibodies. It is uncomfortable and usually self-limited. (Saadah et al.)

Magnitude: About 12 febrile nonhemolytic reactions per 100,000 plasma units.

Intraprocedure blood-pressure and heart-rate swings

The most common adverse events in the Stanford Alzheimer series were hypertension, sinus bradycardia (a slow heart rate), and sinus tachycardia (a fast heart rate), each in 3 of 18 plasma-exposed participants. Events were generally mild to moderate and did not meet the trial’s serious-harm threshold. (Sha et al.)

Magnitude: Each of hypertension, bradycardia, and tachycardia occurred in 16.7% of plasma-exposed participants in that 18-person series.

Citrate anticoagulant in stored plasma binds ionized calcium. Rapid infusion can cause tingling around the mouth, cramp, or, rarely, arrhythmia, especially when several units are given in one sitting. The signal is from transfusion-medicine and apheresis practice, not from longevity-clinic series. (McCarthy et al.)

Magnitude: Not quantified in available studies. Longevity-clinic series have not systematically reported ionized-calcium changes.

Speculative 🟨

Growth-factor promotion of occult neoplasia

Young plasma contains mitogens. No controlled human signal links young-donor plasma to new or faster-growing tumors. The basis is mechanistic only.

Risk-Modifying Factors

  • Antibody status: IgA deficiency with anti-IgA antibodies is the classic anaphylaxis risk. HLA (human leukocyte antigen) sensitization from prior pregnancy or transfusion raises TRALI and allergic risk.
  • Baseline heart and volume status: Elevated natriuretic peptides or uncontrolled blood pressure mark a high-TACO phenotype. Low ionized calcium magnifies citrate effects.
  • Sex: Previously pregnant donors drive much of plasma TRALI; male-only units lower that risk. Recipient-sex effects on adverse events are modest and inconsistent.
  • Heart, kidney, and clotting disease: Heart failure, chronic kidney disease, and prior transfusion reaction dominate risk. Hypercoagulable states (a tendency to form clots) were exclusion criteria in academic trials.
  • Age: Older adults have less cardiovascular reserve and a higher TACO incidence per unit.

Key Interactions & Contraindications

  • Anticoagulants (warfarin, apixaban, rivaroxaban, heparin): Absolute caution. Academic protocols excluded full anticoagulation because plasma adds clotting factors; consequence is thrombosis or unpredictable INR (international normalized ratio, a clotting-time measure). Hold or switch only under a clinician who already manages the anticoagulant.
  • ACE (angiotensin-converting enzyme) inhibitors (lisinopril, enalapril, ramipril): Caution. Plasma can generate bradykinin (a vessel-dilating peptide) and drop blood pressure, especially with some pathogen-reduced products. Holding the dose on infusion day is a common mitigation.
  • Recent IVIG (intravenous immunoglobulin, a pooled antibody infusion) or other human blood products: Caution. Overlapping foreign-protein loads raise allergic risk. Academic trials required a six-month washout.
  • Volume expanders and high-salt intake: Caution. Additive intravascular volume raises TACO risk. Separate large fluid loads from the infusion day.
  • Aspirin, ibuprofen, and other NSAIDs (nonsteroidal anti-inflammatory drugs): Monitor. They raise bruising at the catheter site. Academic protocols often allowed stable low-dose aspirin.
  • Fish oil, high-dose vitamin E, and other bleeding-prone supplements: Monitor. They do not interact with plasma proteins directly but compound bruising if a large intravenous catheter is placed.
  • Therapeutic plasma exchange or albumin dilution: Caution. Combining removal with a later young-plasma fill is a different intervention than additive transfusion and can change circulating volume and clotting-factor load.

Populations who should avoid Young Plasma Transfusion:

  • IgA deficiency with anti-IgA antibodies (anaphylaxis)
  • Uncontrolled heart failure, including NYHA (New York Heart Association) Class III–IV
  • Recent stroke (academic trials used any prior stroke as an exclusion)
  • Uncontrolled hypertension or recent uncontrolled atrial fibrillation
  • Active hypercoagulable disorder or full-dose anticoagulation
  • Prior anaphylaxis or severe reaction to any human blood product
  • Pregnancy
  • Active systemic infection or untreated hepatitis B, hepatitis C, or HIV
  • ABO-incompatible plasma unavailable (no unit matching the A/B/O blood-group system)

Risk Mitigation Strategies

  • Male-never-pregnant donor units: Licensed male-only plasma is the standard TRALI-mitigation unit against donor leukocyte antibodies.
  • Licensed blood-center product: Hospital practice uses ABO-matched, infection-tested fresh frozen plasma from an FDA-registered establishment to cut residual infection and mismatch risk from unlabeled clinic units.
  • Pathogen-reduced plasma when available: Intercept- or solvent-detergent-treated units lower residual virus and some allergic burden.
  • One-unit volume cap: Academic protocols used about 250 mL per visit; large multi-liter clinic loads raise TACO risk.
  • Slow infusion with vital-sign checks: Academic protocols infuse over 1–2 hours and stop for new breathlessness, a sharp blood-pressure rise, or hives.
  • Pre-screen IgA, type-and-screen, and natriuretic peptide: These tests flag anaphylaxis, ABO mismatch, and a high-TACO heart before the first unit.
  • Hold ACE inhibitors on infusion day: Holding the morning dose is a common mitigation of bradykinin-type hypotension during the volume load.

Therapeutic Protocol

Competing approaches are presented side by side; none is a default.

  • Additive young plasma (Sha / Stanford / Alkahest): One unit (~250 mL) of male-donor plasma from donors aged 18–30, once weekly for four weeks, over 1–2 hours.
  • Denser short course (Parker / Stanford Parkinson): One unit twice weekly for four weeks (eight units total) in an infusion chair, then a four-week observation block.
  • Monthly pair (RESET-YOUTH listing): Two units monthly for six months in people over 40; the listing is unverified and has no published results (NCT03353597).
  • Plasma fractions (Alkahest / Grifols): Daily 100–250 mL of GRF6019 or GRF6021 for five days is a proprietary fraction, not whole young plasma.
  • Dilution alternative (Conboy / plasma exchange): Therapeutic plasma exchange with albumin, without young plasma, tests the removal model rather than the additive model.
  • Time of day: No chronobiology data. Daytime infusion-center hours are used so TACO and allergy can be observed.
  • Half-life and splitting: Plasma is a mixture; albumin and immunoglobulin G persist about three weeks, cytokines minutes to hours. Academic work used one unit per visit, not a split daily dose.
  • Genetics: No validated dose change by APOE, MTHFR (a folate-processing gene), or COMT (a catecholamine-clearance gene).
  • Sex: Donor sex is constrained (male-only). Recipient dose is by unit, not by sex.
  • Age: Older recipients need a lower volume and a slower rate because TACO risk rises with age.
  • Baseline biomarkers: Uncontrolled blood pressure, high natriuretic peptides, or IgA deficiency change eligibility more than they change a milliliter dose.
  • Pre-existing disease: Heart failure, stroke history, and full anticoagulation were exclusions in the academic protocols, not titration factors.

Discontinuation & Cycling

  • Duration: Academic use has been a short finite course (four to eight units), not a lifelong replacement.
  • Withdrawal: No withdrawal syndrome is described. Circulating donor proteins fall as they are cleared.
  • Taper: Not applicable. The infusion is stopped; there is no receptor downregulation schedule.
  • Cycling: No evidence that cycling preserves efficacy. Protein half-lives of weeks make monthly repeats biologically plausible and commercially common, but untested for benefit.
  • Rechallenge: A prior allergic reaction is a reason not to repeat, not a reason to titrate.

Sourcing and Quality

  • Licensed establishment: Units from an FDA-registered blood center, labeled as fresh frozen plasma, with documented ABO type and infectious-disease testing.
  • Donor age and sex: Academic work used male donors aged 18–30. Age is recorded on the unit record in those protocols, not inferred from marketing copy.
  • TRALI mitigation: Male-only or never-pregnant female donors; look for the blood center’s plasma-mitigation policy.
  • Pathogen reduction: Intercept, methylene-blue, or solvent-detergent plasma is a licensed option that lowers residual virus when the blood center stocks it.
  • For-profit unlabeled offerings: The FDA 2019 and 2024 notices target for-profit young-plasma offerings that are not given under an investigational new drug application.
  • Not a supplement: Third-party supplement seals do not apply. The quality system is blood-bank accreditation, not a consumer certificate.

Practical Considerations

  • Time to effect: In mice, tissue changes appear within days. In people, no validated longevity marker has a known time-to-effect; exploratory cognitive scores were measured over weeks.
  • Common pitfalls: Treating a clinic listing on ClinicalTrials.gov as FDA approval; confusing additive young plasma with plasma exchange; infusing multi-liter volumes; expecting a biological-age reset from four units.
  • Regulatory status: Fresh frozen plasma is licensed for clotting-factor replacement, not for aging. Young-donor-for-longevity use is off-label and, outside a formal investigational application, is the target of the FDA 2019 and 2024 consumer notices.
  • Cost and access: Ambrosia-era list prices were about $8,000 per infusion. Hospital units cost far less to produce. Neither this use nor elective albumin exchange is typically reimbursed, so public payers have little incentive to fund head-to-head trials.

Interaction with Foundational Habits

  • Sleep: Direct effect is none on a non-infusion night. The volume load, overnight bathroom trips, and citrate symptoms can fragment sleep the night of a unit. No chronic sleep-architecture data exist.
  • Nutrition: Indirect. Plasma adds albumin and other proteins but is not a nutrition intervention. A large salty meal the same day adds volume and TACO risk. Fasting is not required except for paired laboratory draws.
  • Exercise: Potentiating in mechanism, caution in timing. Exercise raises some of the same circulating factors Wyss-Coray studies; a hard session on infusion day adds hemodynamic stress. Mouse work used rest after transfer.
  • Stress management: Indirect and unquantified. Acute psychosocial stress raises inflammatory cytokines that sit in the same milieu young plasma is meant to change. No trial has tested a stress protocol around infusion.

Monitoring Protocol & Defining Success

Baseline testing is a type-and-screen, IgA level, blood count, chemistry panel, natriuretic peptide, and resting blood pressure, done so a licensed ABO-matched unit can be given without an obvious volume or allergy trap. Academic protocols used one unit of about 250 mL, infused over one to two hours with chair-side vital signs. After the first unit, a same-day and next-day check for breathlessness, blood-pressure rise, and low-calcium symptoms is the TACO and citrate watch. If further units are given, that vital-sign and symptom check repeats at each visit; laboratories are typically repeated at the end of a four-week block and again about a month later. Qualitative markers fill the gaps that no aging clock has validated for this procedure.

Ongoing cadence: during each infusion, at 24 hours, at the end of a four-week block, then at about four weeks after the last unit. Longer surveillance has not been standardized.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ABO/Rh type and screen Compatible unit available Prevents ABO-mismatched plasma Before every series; AB plasma is the universal plasma type
Serum IgA Detectable; not deficient Flags anaphylaxis risk IgA-deficient with anti-IgA is a documented anaphylaxis phenotype
NT-proBNP Track vs own baseline; conventional often <125 pg/mL Volume-overload risk NT-proBNP is N-terminal pro–B-type natriuretic peptide, a heart-strain marker. Conventional heart-failure cutoffs are higher; a rise after infusion flags TACO. Not a fasting test.
Blood pressure Individual baseline; not uncontrolled hypertension Intraprocedure swings Recheck during and 1–2 h after infusion
CMP Creatinine stable vs baseline; ionized calcium in lab range Kidney reserve and citrate binding CMP is a comprehensive metabolic panel (creatinine, calcium, albumin). Fasting not required; check calcium if tingling or cramp
CBC Hemoglobin and platelets stable vs baseline Hemodilution, unexpected cytopenias CBC is a complete blood count. Pair with the type-and-screen

Qualitative markers:

  • New breathlessness, orthopnea (breathlessness lying flat), or ankle swelling in the 24 hours after a unit
  • Word-finding and afternoon mental stamina across a four-week block
  • Sleep quality the night of infusion
  • Flushing, hives, or throat tightness during the infusion
  • Tingling around the mouth or muscle cramp (citrate)

No established functional target exists for epigenetic age or a plasma-proteome youth score after this procedure; change from the person’s own baseline is what the literature can support tracking.

Emerging Research

  • Plasma fractions, not whole plasma: Completed Alkahest phase 2 programs of GRF6019 in Alzheimer disease (NCT03520998, NCT03765762) and GRF6021 in Parkinson disease (NCT03713957) test a proprietary young-donor fraction. Safety was acceptable; efficacy remains unproven.
  • Unpublished additive-aging listing: NCT03353597 listed monthly two-unit young-male plasma for epigenetic age in 2,120 adults. Status is unknown, last updated in 2018, and no results have appeared.
  • Withdrawn frailty infusion: NCT04241159 (Wake Forest) of allogeneic young plasma in older adults with frailty was withdrawn at zero enrollment.
  • Dilution can move clocks the other way: A 2025 randomized plasmapheresis trial without young-plasma replacement associated the protocol with higher GrimAge and DunedinPACE (DNA-methylation aging-clock) scores, a finding that weakens any simple “change the plasma, get younger” claim. (Borsky et al.)
  • Old blood induces senescence: A single heterochronic blood exchange spread senescence programs into young mice, supporting the inhibitory-old-plasma model over a purely tonic young-factor model. (Jeon et al.)
  • Isolated platelet factor 4: Exercise-linked platelet factor 4 improved cognition in aged mice, a defined-factor path that could replace whole-plasma units if it holds. (Schroer et al.)

Conclusion

Young plasma transfusion is an unapproved use of a licensed blood product: plasma from a younger donor is infused into an older adult in the hope that circulating youth-associated proteins will restore tissue function. Mouse studies of shared circulation and of injected young plasma show real, short-lived improvements in brain connections, muscle repair, and, in some reports, heart-muscle thickness. Those experiments do not establish a human longevity effect.

The human record is a handful of safety studies, most run with companies that sell processed plasma, in people with memory or movement disorders. Infusions were generally completed without catastrophic events, and a few daily-living or language scores moved without a proper comparison group. No comparison with enough participants has shown that young plasma outperforms a salt-water placebo for cognition, function, or biological age. A competing body of animal work finds that diluting old plasma can reproduce much of the benefit, so adding young plasma while leaving old plasma in place may be the weaker test of the idea.

Plasma still carries the ordinary harms of a volume load and a foreign protein load — allergic reactions, fluid in the lungs, rare lung injury, and a residual infection risk. Much of the published human work comes from groups with a commercial interest in processed plasma, and clinics that charge patients directly have marketed the same product for aging without controlled evidence. For a risk-aware adult optimizing long-term health, the evidence describes an experimentally interesting blood signal, not a demonstrated longevity therapy.

Top - Benefits - Risks - Protocol